The fact that he explicitly is saying this could treat ALL viral diseases makes me skeptical. Maybe I'm wrong, and most viruses produce dsRNA in some form or another during infection.
The fact that he explicitly is saying this could treat ALL viral diseases makes me skeptical. Maybe I'm wrong, and most viruses produce dsRNA in some form or another during infection.
The major issue is that these are macromolecules, and it is incredibly difficult to deliver these in vivo. Every pharmaceutical encounters this problem, and the fact that it isn't really addressed is probably why no companies are biting.
There is some mouse data in the (single) paper, but it is missing some important controls. 1. He never shows that the protein makes it into the cells of the liver/kidney/lung/etc, just that there is some identifiable protein in the organs, and 2. he doesn't control for general immune activation from the injection of the protein, even though he has a control DRACO in the tissue culture experiments.
Also, though it may be overkill, he never shows IFAs of the actual DRACO protein inside the cells from tissue culture.
http://journals.plos.org/plosone/article?id=10.1371/journal....
If that paper is correct, negative strand RNA viruses (https://en.wikipedia.org/wiki/Negative-sense_single-stranded...) would not be treatable with DRACO. And, according to wikipedia, that category includes Ebola, Rabies, Lassa virus and Hanta virus, which is a little disappointing.
But here's the weird part. That wikipedia page also says that Influenza viruses are negative strand RNA viruses, so shouldn't produce dsRNA. But DRACO was tested against H1N1 influenza, and supposedly worked. We have a contradiction. So either the Journal of Virology paper is wrong, wikipedia is wrong is saying that Influenza is a negative strand RNA virus, or DRACO doesn't work against H1N1.
Anyone care to offer some insight?
They include this comment on the Weber (2006) paper cited above:
> their lack of success might relate to the production of smaller amounts of dsRNA in negative-strand RNA virus infections, the use of the less sensitive J2 MAb, the choice of less than optimum times for p.i. sampling, or, possibly, technical issues.